Annual Report

The report describes a year of 6.22% sales growth amid currency and procurement challenges. Renata reported 18 bioequivalence studies, 14 of which were successful, and introduced 76 new formulations. The company also built two factories in Kashor, expanded production capacity across its sites, and augmented its Mirpur R&D facilities.